Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Naveen Vasudev(University of Leeds), Thomas Powles(Queen Mary University of London), Ekaterini Boleti(Royal Free London NHS Foundation Trust), Lisa Pickering(Royal Marsden Hospital), Amit Bahl(At Bristol), Rosamonde E. Banks(Cancer Research UK), Mark Tuthill(Oxford University Hospitals NHS Trust), Fiona Collinson(St James's University Hospital), Galina Velikova(University of Leeds), Balaji Venugopal(Beatson West of Scotland Cancer Centre), Carmel Pezaro(Sheffield Teaching Hospitals NHS Foundation Trust), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Stefan N. Symeonides(NHS Lothian), Janet E. Brown(University of Sheffield), Bernadett Szabados(Queen Mary University of London), Gemma Ainsworth(University of Leeds), Kate Fife(Addenbrooke's Hospital), Anand Sharma(Mount Vernon Hospital), Anthony Maraveyas(University of Hull), Richard W. Griffiths(Clatterbridge Cancer Centre NHS Foundation Trust), Sarah Brown(University of Leeds), Paul Nathan(Mount Vernon Hospital), Eszter Katona(University of Leeds), Helen Howard(University of Leeds), Tom Waddell(The Christie NHS Foundation Trust), Ankit Jain(The Royal Wolverhampton NHS Trust)
Cited by 14
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k